EUCTR2009-016457-18-FI进行中（未招募）不适用
A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain - STRIDE
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Common Inclusion Criteria:
- •1. Male or female between 18 and 90 years of age, inclusive
- •2. Be in good health as determined by the investigator
- •3. Average pain score >=4 during screening period (using the average reported pain from the Brief Pain Inventory [BPI])
- •4. Intact, unbroken skin over the painful area(s) to be treated
- •5. All females of child bearing potential must be willing to use effective methods of birth control during the study and for 30 days following study termination
- •6. Be willing and able to comply with protocol requirements for the duration of study participation
- •7. Subject has given written informed consent
- •Population-specific Inclusion Criteria:
- •All subjects must meet one (and only one) of the Population-Specific Inclusion Criteria for PHN, HIV-AN, PNI or ISNN or have adequately characterized peripheral neuropathic pain based on clinical history and examination:
- •Postherpetic Neuralgia (PHN)
- •Prior diagnosis of PHN with pain persisting at least 3 months since shingles vesicle crusting, documented by the primary treating physician or investigator
- •Painful HIV-Associated Neuropathy (HIV-AN)
- •Confirmation of HIV-AN existing for a minimum of 3 months, as assessed using the Brief Peripheral Neuropathy Screen (BPNS)
- •Peripheral Neuropathic Injury (PNI)
- •Diagnosis of Post-traumatic Peripheral Neuropathic Pain syndrome, including post-surgical neuropathic pain, neuropathic pain due to peripheral nerve injury, confirmed by a qualified pain specialist and persisting for a minimum of 3 months following the traumatic event
- •Idiopathic Small Nerve Neuropathy (ISNN)
- •Diagnosis of ISNN based on clinical and electrodiagnostic criteria:
- •Neuropathy exclusively or predominantly affecting A-d (small myelinated) and nociceptive C (unmyelinated) nerve fibres
- •Loss of pinprick and temperature sensation in feet
- •Other Peripheral Neuropathic Pain (PNP)
- •Adequately characterized peripheral neuropathic pain based on clinical history and examination existing at the time of screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1.Any prior receipt of QUTENZA open label or blinded study patches
- •2.Use of oral or transdermal opioids exceeding a total daily dose of morphine of 80 mg/day, or equivalent; or any parenteral opioids, regardless of dose, within 7 days preceding the first patch application visit.
- •3.Lack of an effective pain medication strategy for the subject, such as unwillingness to use opioid analgesics during study treatment, or high tolerance to opioids precluding the ability to relieve treatment-associated discomfort with oxicodone or other analgesic, as judged by the investigator
- •4.Active substance abuse or history of chronic substance abuse within 1 year prior to enrolment or prior chronic substance abuse (including alcoholism) judged likely to re-occur during the study period by the investigator
- •5.Use of any topical pain medication, such as non-steroidal anti-inflammatory drugs, menthol, methyl salicylate, local anaesthetics, steroids or capsaicin products on the painful areas within 7 days preceding the first patch application visit
- •6.Current use of any investigational agent (excluding antiretrovirals in Phase 3 evaluation to treat HIV infection)
- •7.Unstable or poorly controlled hypertension or a recent history of a cardiovascular event which, in the opinion of the investigator, would put the patient at risk of adverse cardiovascular reactions related to the patch application procedure
- •8.Evidence of another contributing cause for peripheral neuropathy, and/or treatment within 90 days prior to screening visit with any drug that may have contributed to the sensory neuropathy
- •9.Past or current history of Type I or Type II diabetes mellitus
- •10.Current psychotic disorders
- •11.Clinically significant abnormal ECG at screening
- •12.Hypersensitivity to capsaicin (i.e., chilli peppers or Over-the-counter [OTC] capsaicin products),any QUTENZA excipients, local anaesthetics, oxycodone, hydrocodone, or adhesives
- •13.Significant ongoing or untreated abnormalities in cardiac, renal, hepatic, or pulmonary function that may interfere either with the ability to complete the study or the evaluation of adverse events
- •14.Significant pain of an aetiology other than painful HIV-AN, PHN, PNI, ISNN or other adequately characterized peripheral neuropathic pain for example, compression-related neuropathies (e.g., spinal stenosis), fibromyalgia or arthritis
- •15.Posttraumatic neuropathic pain due to Complex Regional Pain Syndrome (CRPS, Type I)
- •16.Active malignancy or history of malignancy during the past 5 years (a history of squamous cell carcinoma or a basal cell carcinoma not involving the area to be treated is allowed)
- •17.Evidence of cognitive impairment including dementia that may interfere with subject’s ability to complete study evaluations and recall pain levels in the past 24 hours
- •18.Planned elective surgery during the trial
- •19.Neuropathic pain areas located only on the face, above the hairline of the scalp, and/or in proximity to mucous membranes.
- •20.Female subjects of child-bearing potential with a positive serum or urine pregnancy test prior to treatment
研究者
相似试验
进行中（未招募）
不适用
A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain - STRIDEEUCTR2009-016457-18-GRAstellas Pharma Europe Ltd300
进行中（未招募）
1 期
A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain - STRIDEPeripheral Neuropathic Pain in Postherpetic Neuralgia (PHN), Painful HIV-Associated Neuropathy (HIV-AN), Peripheral Neuropathic Injury (PNI), Idiopathic Small Nerve Neuropathy (ISNN) or other Peripheral Neuropathic Pain (PNP).MedDRA version: 12.1Level: LLTClassification code 10054095Term: Neuropathic painEUCTR2009-016457-18-SKAstellas Pharma Europe Ltd300
进行中（未招募）
1 期
A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain - STRIDEPeripheral Neuropathic Pain in Postherpetic Neuralgia (PHN), Painful HIV-Associated Neuropathy (HIV-AN), Peripheral Neuropathic Injury (PNI), Idiopathic Small Nerve Neuropathy (ISNN) or other Peripheral Neuropathic Pain (PNP).MedDRA version: 14.1 Level: LLT Classification code 10054095 Term: Neuropathic pain System Organ Class: 100000004852EUCTR2009-016457-18-GBAstellas Pharma Europe Ltd306
进行中（未招募）
1 期
A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain - STRIDEEUCTR2009-016457-18-BEAstellas Pharma Europe Ltd300
进行中（未招募）
不适用
A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain - STRIDEPeripheral Neuropathic Pain in Postherpetic Neuralgia (PHN), Painful HIV-Associated Neuropathy (HIV-AN), Peripheral Neuropathic Injury (PNI), Idiopathic Small Nerve Neuropathy (ISNN) or other Peripheral Neuropathic Pain (PNP).MedDRA version: 14.1Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 100000004852EUCTR2009-016457-18-ATAstellas Pharma Europe Ltd300